Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
|
30883868 |
2019 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Gastroesophageal reflux disease (GERD) can be treated using a vonoprazan-first strategy (first-line treatment with vonoprazan), or esomeprazole-first/rabeprazole-first strategies (first-line treatment with proton-pump inhibitors [PPIs], esomeprazole/rabeprazole, followed by a switch to vonoprazan).
|
31396703 |
2019 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the current systematic review and network meta-analysis (NMA) was to assess the diagnostic characteristics of the gastroesophageal reflux disease questionnaire (GERDQ), proton-pump inhibitor (PPI) test, baseline impedance, mucosal impedance, dilated intercellular spaces (DIS), salivary pepsin, esophageal pH/pH impedance monitoring and endoscopy for gastroesophageal reflux disease (GERD).
|
31803253 |
2019 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
|
30919071 |
2019 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to assess the dynamic changes in the peripheral T lymphocytes and lymphocytes infiltrating the esophageal mucosa after treatment with proton-pump inhibitor (PPI) in patients with GERD.
|
30119091 |
2019 |
Gastroesophageal reflux disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The main causes of refractory heartburn include: poor compliance; inadequate proton-pump inhibitors dosage; incorrect diagnosis; comorbidities; genotypic differences; residual gastroesophageal reflux; eosinophilic esophagitis and others.
|
29352757 |
2018 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secondary endpoints included cessation of proton-pump inhibitor (PPI), persistent dysphagia requiring intervention, and GERD health-related quality-of-life (HRQL) scores 1 year from surgery.
|
29340828 |
2018 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study was aimed at evaluating, in dysphagic patients, the role of high-resolution manometry (HRM) findings, presence of gastroesophageal reflux disease (GERD), and proton-pump inhibitor (PPI) therapy on dysphagia perception.
|
28787356 |
2018 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is due to multiple factors, including overlaps in presentation with gastroesophageal reflux disease and proton-pump inhibitor responsive eosinophilia, remaining uncertainties regarding the role of different forms of allergy testing, and a variety of patient adherence issues.
|
30401322 |
2018 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Higher economic status, smoking, and a history of proton-pump inhibitor use significantly increased the risk of GERD.
|
30427843 |
2018 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subgroup analysis was performed among studies that excluded gastroesophageal reflux disease or proton-pump inhibitor responsive esophageal eosinophilia, and also among pediatric and adult populations.
|
28787360 |
2018 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
GERD is a clinical diagnosis and is most effectively treated with proton-pump inhibitors (PPIs).
|
29132520 |
2017 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Especially when proton-pump inhibitors failed to improve symptoms, other diagnosis should be considered, such as functional laryngeal disorders which are probably much more prevalent in these patients than pathologic gastroesophageal reflux.
|
28858946 |
2017 |
Gastroesophageal reflux disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Retrospective analysis of LSG+sLHR patients >5 months postoperatively includes demographics, GERD status, proton-pump inhibitor (PPI) use, body mass index (BMI), excess BMI loss (EBMIL), complications and GERD-Health Related Quality of Life (GERD-HRQL) questionnaire.
|
27896401 |
2017 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
H2-receptor antagonists and proton-pump inhibitors provide more effective options for remission of GERD symptoms and healing of esophagitis.
|
28321555 |
2017 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Food and Drug Administration approval of proton-pump inhibitors for infantile gastroesophageal reflux disease has been limited by intrapatient variability in the clinical assessment of gastroesophageal reflux disease.
|
27875488 |
2017 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The reflux of pancreatic-duodenal fluids is implicated in the pathophysiology of proton-pump inhibitor-resistant gastroesophageal reflux disease (GERD).
|
26233549 |
2015 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associations were additionally tested for the confounding effect of covariates associated with a diagnosis of GERD and the use of proton-pump inhibitor medications (PPIs).
|
24894541 |
2014 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The proton-pump inhibitor (PPI) test has been proposed as a valuable tool for diagnosing gastroesophageal reflux disease in Western populations.
|
19407662 |
2010 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Maintenance therapy of gastroesophageal reflux disease (GERD) is usually performed with a low dose of a proton-pump inhibitor (PPI).
|
19259653 |
2009 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
|
17559380 |
2007 |
Gastroesophageal reflux disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggests that CYP2C19 genotype testing will not be useful in proton-pump inhibitor therapy of GERD, except perhaps in identifying patients at risk for hypochlorhydria and consequent hypergastrinemia.
|
12823155 |
2003 |